看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 22.6x - 25.0x | 23.8x |
| Selected Fwd EBIT Multiple | 16.6x - 18.4x | 17.5x |
| Fair Value | €140.97 - €157.92 | €149.45 |
| Upside | 21.2% - 35.7% | 28.4% |
| Benchmarks | Ticker | Full Ticker |
| Regeneron Pharmaceuticals, Inc. | REGN | NasdaqGS:REGN |
| AbbVie Inc. | ABBV * | BMV:ABBV* |
| Amgen Inc. | AMGN | NasdaqGS:AMGN |
| Gilead Sciences, Inc. | GILD | NasdaqGS:GILD |
| Intellia Therapeutics, Inc. | NTLA | NasdaqGM:NTLA |
| CSL Limited | CSJ | DB:CSJ |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| REGN | ABBV * | AMGN | GILD | NTLA | CSJ | ||
| NasdaqGS:REGN | BMV:ABBV* | NasdaqGS:AMGN | NasdaqGS:GILD | NasdaqGM:NTLA | DB:CSJ | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 13.4% | 5.2% | -0.1% | 2.7% | NM- | 8.6% | |
| 3Y CAGR | -22.8% | -2.5% | 1.9% | -3.6% | NM- | 11.9% | |
| Latest Twelve Months | -3.4% | 13.7% | 10.8% | 8.3% | 2.3% | 5.3% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 40.0% | 34.7% | 34.5% | 40.1% | -843.0% | 27.8% | |
| Prior Fiscal Year | 32.3% | 32.5% | 34.3% | 34.2% | -1420.5% | 26.3% | |
| Latest Fiscal Year | 29.2% | 32.5% | 28.9% | 37.2% | -923.1% | 26.4% | |
| Latest Twelve Months | 27.8% | 34.0% | 30.8% | 38.2% | -968.7% | 26.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 3.14x | 7.54x | 5.60x | 5.53x | 10.78x | 5.01x | |
| EV / LTM EBITDA | 10.0x | 15.7x | 12.1x | 11.6x | -1.1x | 15.9x | |
| EV / LTM EBIT | 11.3x | 22.2x | 18.2x | 14.5x | -1.1x | 19.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -1.1x | 14.5x | 22.2x | ||||
| Historical EV / LTM EBIT | 19.0x | 30.0x | 32.4x | ||||
| Selected EV / LTM EBIT | 22.6x | 23.8x | 25.0x | ||||
| (x) LTM EBIT | 4,104 | 4,104 | 4,104 | ||||
| (=) Implied Enterprise Value | 92,773 | 97,656 | 102,538 | ||||
| (-) Non-shareholder Claims * | (11,413) | (11,413) | (11,413) | ||||
| (=) Equity Value | 81,360 | 86,243 | 91,125 | ||||
| (/) Shares Outstanding | 484.9 | 484.9 | 484.9 | ||||
| Implied Value Range | 167.80 | 177.87 | 187.94 | ||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | |||
| Implied Value Range (Trading Cur) | 143.24 | 151.83 | 160.43 | 116.36 | |||
| Upside / (Downside) | 23.1% | 30.5% | 37.9% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | REGN | ABBV * | AMGN | GILD | NTLA | CSJ | |
| Enterprise Value | 44,221 | 438,505 | 195,406 | 158,919 | 741 | 77,506 | |
| (+) Cash & Short Term Investments | 7,470 | 6,467 | 8,028 | 6,058 | 460 | 2,157 | |
| (+) Investments & Other | 10,467 | 370 | 5,471 | 2,640 | 197 | 0 | |
| (-) Debt | (2,705) | (70,585) | (56,204) | (24,946) | (103) | (11,498) | |
| (-) Other Liabilities | 0 | (45) | 0 | 84 | 0 | (2,072) | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 59,452 | 374,712 | 152,701 | 142,755 | 1,295 | 66,093 | |
| (/) Shares Outstanding | 103.7 | 1,766.6 | 538.4 | 1,240.8 | 107.3 | 484.9 | |
| Implied Stock Price | 573.38 | 212.11 | 283.64 | 115.05 | 12.06 | 136.32 | |
| FX Conversion Rate to Trading Currency | 1.00 | 0.05 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 573.38 | 3,969.25 | 283.64 | 115.05 | 12.06 | 116.36 | |
| Trading Currency | USD | MXN | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 0.05 | 1.00 | 1.00 | 1.00 | 1.17 | |